Rabbit (JW) |
peptide vaccine |
Inoculum (IV)EBV (B95-8) |
EBV-DNA quantity in blood (copies/106 cells) |
maximum EBV-DNA in blood (copies/106 cells) |
Increase in anti-EBV antibody titer |
observation period (days) |
EBER-1 expression* in necropsy materials |
N-36 |
−a |
9.2×107 copies |
9.4×101 (4 days) |
6.6×104 (9 days) |
ND |
28, killed |
positive** (++) |
N-38 |
− |
9.2×106 copies |
1.8×101 (4 days) |
9.6×102 (8 days) |
ND |
28, killed |
positive (++) |
N-82 |
− |
9.2×105 copies |
1.7×104 (14 days) |
1.7×104 (14 days) |
ND |
49, died |
positive (+) |
N-83 |
− |
9.2×104 copies |
5.3×101 (21 days) |
1.3×103 (28 days) |
+ (EA-IgG), − (VCA-IgM, VCA-IgG, EBNA-IgG) |
91, killed |
positive (+), a few |
N-84 |
− |
9.2×104 copies |
negative |
negative |
− (VCA-IgM, VCA-IgG, EBNA-IgG, EA-IgG) |
70, killed |
positive (+) |
P-204 |
− |
9.2×104 copies |
negative |
negative |
ND |
70, killed |
positive (+) |
P-206 |
− |
9.2×104 copies |
negative |
negative |
ND |
70, killed |
positive (+), a few |
O-19 |
+ |
9.2×104 copies |
1.3×103 (35 days) |
1.3×103 (35 days) |
− (VCA-IgM, VCA-IgG, EBNA-IgG, EA-IgG) |
49, died |
positive (+++) |
O-21 |
+ |
9.2×104 copies |
negative |
negative |
− (VCA-IgM, VCA-IgG, EBNA-IgG, EA-IgG) |
70, killed |
negative |
O-22 |
+ |
9.2×104 copies |
negative |
negative |
ND |
42, died |
positive (+), few |
L-143 |
+ |
9.2×104 copies |
negative |
negative |
− (VCA-IgM, VCA-IgG, EBNA-IgG, EA-IgG) |
70, killed |
positive (+), a few |
O-208 |
+ |
9.2×104 copies |
negative |
negative |
ND |
119, killed |
positive (+), few |
O-209 |
+ |
9.2×104 copies |
negative |
negative |
ND |
119, killed |
positive (+), few |
VCA: viral capsid antigen; JW: Japanese White; EBNA: EBV-associated nuclear antigen; EA: early antigen; ND: not determined |
|
*: EBV-encoded RNA expression examined by in situ hybridization (ISH); **: EBER-1-positive lymphocytes
EBER-1 positive: (+++), more than 15%; (++), 5% – 15%; (+), 1% –less than 5%; (+) a few, 3 positive cells– less than 1%/ section; (+) few, 1 – 2 positive cells/section. |
a:indicates treatment with keyhole-limpet hemocyanin and adjuvant without peptides before EBV inoculation. |
|